147

therapeutic
published patents

56

oncology
published patents

310

research tools

46

diagnostic
published patents

Our Technology Offers

Welcome to our Technology Offers website

You want access to an innovative offer which is based on the excellence of Inserm, the leading academic research and clinical institute dedicated to human health in Europe? Find out our technologies offers of patents and research tools: here is a sample of our patents.

Applications
Therapy areas
Download
More posts

Use of cd9 as a biomarker and as a biotarget in glomerulonephritis

The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) […]

Use of inhibitors of the hippo signalling pathway for the treatment of

Chronic nephropathies represent a real global public health concern. In particular, nephronophthisis (NPH) is an orphan genetic disease affecting the […]

Methods and pharmaceutical composition for treating ciliopathies

Inventors have found that CB1 inhibition (genetic invalidation or using a pharmacological peripheral blockade) reduces CKD and fibrosis in the severe […]

Methods and pharmaceutical compositions for the treatment of autosomal

Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disease affecting 1 in 1,000 to 1 in 2,500 individuals worldwide. The […]

Methods and kits for diagnosing cause of nephrotic syndrome and

The present invention describes the identification of a soluble glomerular permeability factor, anti-Vasorin (or anti-VASN) autoantibodies synthesized […]

New prognostic method of kidney failure

The present invention relates to the prediction of kidney injury. In this study, the inventors studied the transcriptomic landscape in AAV-GN to find […]

Vasorin as a biomarker and biotarget in nephrology

Aiming to identify factors underlying podocytes loss, the inventors revealed a markedly decreased expression of Vasorin (VASN) using comparative deep […]

Ngal as a biomarker for predicting the evolution and treatment of

The severity of renal lesions after nephron reduction varied substantially among mouse strains and required activation of EGFR. Lipocalin 2 (Lcn2, […]

Cd9 as a new biomarker for diagnosing or predicting risk of

The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) […]

Ppar-gamma agonist as target for the treatment of rapidly progressive

This study demonstrates the pivotal role of the local PPAR-gamma agonist system in maintaining podocyte quiescence and orchestrating the global […]

You might also be interested in